Emapalumab: all 21 studies that test it

Page 1 of 1. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.

• Severe Hepatitis Intervention With Emapalumab for Liver DiseaseNot yet recruitingNCT07744919Phase 2
• Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANSNot yet recruitingNCT07567014Phase 2
• Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft DysfunctionNot yet recruitingNCT07538336Phase 2
• Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) StudyRecruitingNCT07486869Phase 2
• Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) RecipientsRecruitingNCT07244419Early Phase 1
• Randomized Stepped Wedge Study of Emapalumab in APECED EnteritisRecruitingNCT07202598Phase 2
• Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell TransplantRecruitingNCT06996119Phase 1
• A Study of Emapalumab for Pediatric Aplastic AnemiaRecruitingNCT06430788Phase 2
• A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged CytopeniaRecruitingNCT06285825Phase 2
• A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory ConditionRecruitingNCT05787574Phase 2
• A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese PatientsCompletedNCT05744063Phase 4Results posted
• Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLECompletedNCT05001737Phase 3Results posted
• A Study to Evaluate Emapalumab in Japanese Healthy Volunteers.CompletedNCT04765553Phase 1Results posted
• Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.TerminatedNCT04731298Phase 2Results posted
• Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.TerminatedNCT04324021Phase 2/3Results posted
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLHTerminatedNCT03985423Phase 2/3Results posted
• Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic LymphohistiocytosisCompletedNCT03312751Phase 3Results posted
• A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)CompletedNCT03311854Phase 2Results posted
• A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal AntibodyCompletedNCT02069899Phase 2/3Results posted
• Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic LymphohistiocytosisCompletedNCT01818492Phase 2/3Results posted
• First in Human Study of an Anti-IFN Gamma Monoclonal Antibody in Healthy VolunteersCompletedNCT01459562Phase 1

← Emapalumab overview